Tripos Names New VP of Marketing and Corporate Development, Discovery Informatics
News Dec 16, 2005
Tripos, Inc. has announced that it has appointed Kathleen Mensler as vice president of marketing and corporate development, Discovery Informatics.
In this role, Mensler will oversee worldwide marketing, manage existing alliances, seek new business relationships and contribute to the strategic direction for the growth and expansion of Tripos’ Discovery Informatics business.
"Kathleen is an experienced leader who holds a strong performance record in helping grow products and expand companies in the life science industry," said Bryan Koontz, senior vice president and general manager of Discovery Informatics at Tripos.
"Her deep knowledge of business, science and informatics, combined with her intuitive understanding of customer needs, will be a tremendous asset to Tripos."
Mensler brings 20 years of business and marketing experience in life science informatics to Tripos.
Most recently, she served as vice president of business development at Elsevier MDL.
She has also held executive-level positions in marketing, product development and business management at MDL, and established its consulting and customer service organizations. Before her tenure at MDL, Mensler worked as a medicinal chemist at Merck, Inc.
"Throughout its history, Tripos has been an innovator in chemical informatics," Mensler said.
"Now the company is poised to have even greater impact on its customers’ discovery science and processes."
"I am excited to join the Tripos team and look forward to contributing to a new era at Tripos."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE